SOURCE: Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc. Logo

June 03, 2016 11:15 ET

Lion Biotechnologies to Present at the Jefferies 2016 Healthcare Conference

NEW YORK, NY--(Marketwired - June 03, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced today that Lion management will present a company overview at the upcoming Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 2:30pm E.T in New York, NY.

A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/. A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.

About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.

Forward-Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including risks related to the Company's ability to complete its ongoing Phase 2 study of LN-144 and the other risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Investor Relations Contact:
    Sarah McCabe
    Stern Investor Relations, Inc.
    Office: 212-362-1200

    Media Relations Contact:

    Jody LoMenzo
    inVentiv Health Public Relations
    Office: 212-364-0458
    Mobile: 646-866-1721